Trial Profile
An Open-Label, Multicenter, Phase 4 Study to Demonstrate the Prognostic Usefulness of AdreView Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2017
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Heart failure
- Focus Diagnostic use
- Sponsors GE Healthcare
- 02 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to the United Kingdom Clinical Research Network record.
- 02 Feb 2015 New trial record